Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue derived from the 4-7 fragment of adrenocorticotropic hormone (ACTH), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax has been registered as a pharmaceutical product in Russia and Ukraine, providing a clinical research context unusual for peptides in this class.
BDNF Expression and Neurotrophin Research
One of the most studied aspects of Semax involves its effects on BDNF expression. Preclinical research has documented significant upregulation of BDNF mRNA in various brain regions following Semax administration in rodent models, including hippocampus, frontal cortex, and striatum.
Melanocortin Receptor Interaction Research
Research has examined Semax's interactions with melanocortin receptors, particularly MC4R, given the structural homology of its core sequence with the MC receptor-binding domain of ACTH.
Dopaminergic and Serotonergic System Research
Preclinical research has examined Semax's interactions with monoaminergic neurotransmission systems, including its effects on dopamine and serotonin turnover in brain regions associated with cognitive regulation.
• Dolotov OV et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
